Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

CrowdStrike Soars High in IT Security Sector

Daniel Kim Views  

CrowdStrike (CRWD) has been named a “Top Pick” in the global IT security center.

CrowdStrike has expanded its market share with an integrated endpoint security solution named Falcon. Falcon, a first-of-its-kind single platform, single console (interface) security solution, is praised for its ability to solve the complexities and operational difficulties at a time when businesses are looking to enhance their security using more security solutions.

“The reason CRWD was able to proliferate in a short time is because it quickly seized a new market when the IT environment was changing to the cloud,” said Kim Soo Jin, a researcher at Mirae Asset Securities. “While established players like McAfee and Symantec failed to transition from a legacy to the cloud, the company quickly expanded its market share with AI technology at the forefront,” she analyzed.

Despite Microsoft aggressively entering the endpoint security market in 2022, analysis shows that CrowdStrike maintains a high growth rate thanks to its existing references and technical capabilities.

Researcher Kim Soo Jin recommended CrowdStrike as the top pick in the global IT security sector, citing its leading technology and sales capabilities, strong performance growth, business margin turnaround, and stable cash flow, all led by Falcon.

On March 10, CrowdStrike again surprised the market with its earnings announcement. The company’s fourth-quarter revenue for the fiscal year 2024 increased by 33% compared to the previous year, reaching $845 million (USD). Its non-GAAP EPS exceeded expectations, recording $0.95. The profit improvement was also notable, with the non-GAAP operating profit margin recording 25%, marking the first time the operating profit margin has settled in the 20% range.

The guidance for the first quarter of the fiscal year 2025 exceeded market expectations, projecting revenues of $902 to $906 million and non-GAAP EPS of $0.89 to $0.90.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[BUSINESS] Latest Stories

  • Honda's NSX Returns: A 1,000-Horsepower Electric Rival to Lexus LFR
  • Honda’s S7 Electric SUV: A Major Player in the Race for EV Dominance
  • Lamborghini's First EV: A 2,000-Horsepower Beast Built for Speed and Emotion
  • Ford Revives Classic Design with the 2025 Bronco Heritage Edition
  • ID.EVERY1: Volkswagen's $21K Electric Vehicle Aims to Make Green Driving Accessible
  • Toyota’s bZ3X SUV Surges with 10,000 Pre-Orders: A New Era in EVs

You May Also Like

  • 1
    FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections

    LIFESTYLE 

  • 2
    Prostate Cancer Screenings May Cut Death Risk in Half, Study Finds

    LIFESTYLE 

  • 3
    It’s Not Just Depression: Personality Disorders Linked to Highest Suicide Risk

    LIFESTYLE 

  • 4
    Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

    LIFESTYLE 

  • 5
    Cutting Carbs? You Might Be Raising Your Risk of Colon Cancer

    LIFESTYLE 

Popular Now

  • 1
    Tired of the Buzz? Fruit and Dairy Might Help, New Study Says

    LIFESTYLE&nbsp

  • 2
    Study Finds Missing Gut Bacteria in Parkinson’s and IBD Patients

    LIFESTYLE&nbsp

  • 3
    New Research Reveals Ketogenic Diet Slows Biological Aging by 6+ Years

    LIFESTYLE&nbsp

  • 4
    New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects

    LIFESTYLE&nbsp

  • 5
    Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment

    LIFESTYLE&nbsp

Must-Reads

  • 1
    FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections

    LIFESTYLE 

  • 2
    Prostate Cancer Screenings May Cut Death Risk in Half, Study Finds

    LIFESTYLE 

  • 3
    It’s Not Just Depression: Personality Disorders Linked to Highest Suicide Risk

    LIFESTYLE 

  • 4
    Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

    LIFESTYLE 

  • 5
    Cutting Carbs? You Might Be Raising Your Risk of Colon Cancer

    LIFESTYLE 

Popular Now

  • 1
    Tired of the Buzz? Fruit and Dairy Might Help, New Study Says

    LIFESTYLE 

  • 2
    Study Finds Missing Gut Bacteria in Parkinson’s and IBD Patients

    LIFESTYLE 

  • 3
    New Research Reveals Ketogenic Diet Slows Biological Aging by 6+ Years

    LIFESTYLE 

  • 4
    New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects

    LIFESTYLE 

  • 5
    Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment

    LIFESTYLE